

# Atte Nikkilä

✉ [atte.nikkila@tuni.fi](mailto:atte.nikkila@tuni.fi)

🌐 [atte.nikki.lat](http://atte.nikki.lat)

📞 [0000-0003-0292-2386](tel:0000-0003-0292-2386)

## Current position

2024	Pediatric Resident Pediatrics department, Tampere University Hospital, Finland
2019	Post-doctoral researcher HemoRes group, TamCAM - Tampere Center for Child, Adolescent and Maternal Health Research Faculty of Medicine and Health Technology, Tampere University, Finland

## Education

2019	Licentiate of Medicine (M.D.) MD PhD program, Faculty of Medicine and Health Technology, Tampere University, Finland
2019	Doctor of Medicine (Ph.D.) MD PhD program, Faculty of Social Sciences, Tampere University, Finland
2023	Title of Docent / Associate professor Faculty of Medicine and Health Technology, Tampere University, Finland
2022	General Practice Special Education (EU cert.) Faculty of Medicine and Health Technology, Tampere University, Finland
Ongoing	Pediatrician, specialist degree Faculty of Medicine and Health Technology, Tampere University, Finland

## Past positions

2014–2019	<i>Doctoral student</i> Faculty of Medicine and Health Technology, Tampere University, Finland
2019–2020	Pediatric Resident Pediatric Outpatient Unit, Tampere, Finland
2021–2023	Pediatric Resident Pediatrics department, Kanta-Häme Central Hospital, Finland

## Other experience

- Supervision of M.D. theses and a Ph.D. thesis
- Formal university-level pedagogical education
- High-level data analysis and presentation using R language
- Good skills with Redcap and Python, experience using HTML, CSS, MySQL, C++, PowerShell, Unix
- Management and organization of international collaborations
- Personal and project grants nearing 100k€ from Väre foundation, Pediatrics Research Foundation, Finnish Cultural Foundation, Tampere Science Foundation, Tampere Physician Association, State Competitive Research Funding.

## Languages

Finnish	Native proficiency
English	Full professional proficiency
Swedish	Limited working proficiency
French	Elementary proficiency

## Scientific distinctions

2016	Excellent Poster Presentation, Tampereen Lääkäripäivät
2016	M.D. thesis approved with distinction
2016, 2018	Finalist, Young Epidemiologist of the Year (Finnish Epidemiology Association)
2017	Best Oral Presentation, Science Day, Faculty of Medicine, Tampere University
2019	Ph.D. thesis approved with distinction
2022	Finalist, Young Scientist of the Year (Finnish Pediatrician Association)

## Selected publications

**Nikkilä A**, Lohi O, Nieminen N, Csonka P. Trends in ferritin measurements in children and adolescents: A Finnish 9-year observational study. *Acta Paediatrica* [Internet]. n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/apa.16454>

**Nikkilä A**, Arvela H, Mehtonen J, Raitanen J, Heinäniemi M, Lohi O, et al. Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. *Scand J Work Environ Health* [Internet]. 2019 Nov 25 [cited 2020 Jan 8]; Available from: [http://www.sjweh.fi/show\\_abstract.php?abstract\\_id=3867](http://www.sjweh.fi/show_abstract.php?abstract_id=3867)

**Nikkilä A**, Raitanen J, Lohi O, Auvinen A. Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). *Haematologica*. 2018 Nov;103(11):1873–80.

**Nikkilä A**, Erme S, Arvela H, Holmgren O, Raitanen J, Lohi O, et al. A nationwide register-based case-control study: Background Radiation and Childhood Leukemia. *Int J Cancer*. 2016 Nov 1;139(9):1975–82.

Abuhamed J, **Nikkilä A**, Raitanen J, Alimam W, Lohi O, Pitkaniemi J, et al. Incidence trends of childhood central nervous system tumors in Finland 1990–2017. *BMC Cancer*. 2022 Dec;22(1):784.

Oksa L, Mäkinen A, **Nikkilä A**, Hyvärinen N, Laukkanen S, Rokka A, et al. Arginine Methyltransferase PRMT7 Dereglates Expression of RUNX1 Target Genes in T-Cell Acute Lymphoblastic Leukemia. *Cancers*. 2022 Apr 26;14(9):2169.

Ventelä J, **Nikkilä A**, Jukkola A, Lohi O. Incidence and outcomes of cancer in 16- to 17-year-old adolescents. *Acta Paediatr*. 2021 Nov 11;apa.16161.

Mäkinen A, **Nikkilä A**, Haapaniemi T, Oksa L, Mehtonen J, Vänskä M, et al. IGF2BP3 Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia. 2021;12.

Immonen E, Aine L, **Nikkilä A**, Parikka M, Grönroos M, Vepsäläinen K, et al. Randomized controlled and double-blinded study of Caphosol versus saline oral rinses in pediatric patients with cancer. *Pediatr Blood Cancer* [Internet]. 2020 Oct [cited 2020 Sep 3];67(10). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.28520>

Endén K, Tainio J, **Nikkilä A**, Helanterä I, Nordin A, Pakarinen MP, et al. Cancer morbidity and mortality after pediatric solid organ transplantation—a nationwide register study. *Pediatric Nephrology* [Internet]. 2020 May 11 [cited 2020 May 13]; Available from: <http://link.springer.com/10.1007/s00467-020-04546-y>

Poukka M, Lund-Aho T, Raitinen P, **Nikkilä A**, Kivinen K, Lundán T, et al. Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment: *Journal of Pediatric Hematology/Oncology*. 2018 Jul;1.



1<sup>st</sup> April 2024, Tampere